EC Fees Sample Clauses

EC Fees. Sponsor shall reimburse Institution for EC fees in connection with the Study listed in the attached Budget. If Institution will be using the central EC, Sponsor will pay Institution’s EC fees directly to the central EC designated by Sponsor for the Study and will not reimburse Institution for EC fees incurred in connection with the Study. 7. Poplatky pro etickou komisi. Zadavatel nahradí zdravotnickému zařízení poplatky pro etickou komisi ve spojitosti se studií uvedené v přiloženém rozpočtu. Pokud zdravotnické zařízení použije ústřední etickou komisi, zadavatel zaplatí poplatky zdravotnického zařízení pro etickou komisi přímo ústřední etické komisi, kterou zadavatel určí pro studii, a nenahradí zdravotnickému zařízení poplatky etické komisi ve spojitosti se studií.
AutoNDA by SimpleDocs
EC Fees. Další náklady
EC Fees. Central and local Ethics Committee fees will be paid directly by CRO/Pfizer unless otherwise specified herein. Odměna EK: Poplatky centrální a lokální etické komisi budou hrazeny přímo CRO/společností Pfizer, pokud v tomto dokumentu není specifikováno jinak. Please indicate following on the Subject line: Sponsor name; Study Protocol #, Project code # 00XXX0000 and PI name Do předmětu zprávy uveďte následující: jméno zadavatele; č. Protokolu studie, kód projektu 00XXX0000 a jméno Hlavního zkoušejícího Correspondence should be addressed to the Grants Management mailbox below: Email Korespondence musí být adresována oddělení Grants Management na adresu: Email: Please indicate following on the Subject line: Sponsor name; Study Protocol #, Project code # Do předmětu zprávy uveďte následující: jméno zadavatele; č. Protokolu studie, kód 00XXX0000 and PI name projektu 00XXX0000 a jméno Hlavního zkoušejícího Invoices should not be submitted until approval has been received from CRO and/or Pfizer to begin enrollment. Invoices will not be paid until such time. If invoices are received prior to approval to begin enrollment, they will not be processed and payment will be delayed. Faktury by neměly být předkládány, dokud neobdržíte souhlas CRO a/nebo společnosti Pfizer se zahájením náboru subjektů. Do takového okamžiku faktury nebudou propláceny. Pokud budou přijaty faktury před souhlasem se zahájením náboru, nebudou zpracovány a platba bude opožděna. For any costs not in Exhibit 1, do not submit invoices until a budget modification letter or contract amendment has been received. To expedite payment, such invoices can be accompanied by a copy of the amendment. Za náklady neuvedené v příloze č. 1 nepředkládejte faktury, dokud neobdržíte dopis o úpravě rozpočtu nebo dodatek ke Smlouvě. K urychlení plateb by k fakturám měla být přiložena kopie takového dodatku. The following information must be included on all invoices: • Invoice numberInvoice date • CZK amount of invoice • Principal Investigator NameInstitution NameProtocol Number • CRO project NumberDate of event (visit or procedure as applicable) Následující informace musí být uvedeny na všech fakturách: • Číslo faktury • Datum vystavení faktury • Fakturovaná částka v Kč • Jméno Hlavního zkoušejícího • Název Instituce • Číslo Protokolu • Číslo projektu CRO • Termín konání (návštěvy nebo procedury dle potřeby) Invoices for additional treatment-related costs, other study level costs that are pre-approved by CR...
EC Fees. IRB costs will be reimbursed directly to the IRB by CRO on a pass-through basis upon receipt of invoice and are not included in the attached Budget. Any subsequent re-submissions or renewals, upon approval by CRO and Sponsor, will be reimbursed upon receipt of invoice.
EC Fees. All fees related to Ethics Committees (MEC and LEC) and Regulatory Authority (RA) are paid by PPD and/or Sponsor apart from this Agreement or Exhibit 1. Ďalšie priebežné náklady súvisiace so skúšaním: Ďalšie priebežné náklady súvisiace s klinickým skúšaním, ako sú definované v rozpočte – Príloha 1, sa uhradia zdravotníckemu zariadeniu na základe doručenej faktúry. Other pass through costs: Other incurred pass through costs as defined in the study Exhibit 1 – Budget will be paid to the Institution upon receipt of invoice notification to Sponsor/PPD of full execution of the Agreement. Porušenie protokolu: Platby nebudú uhradené v prípade, že pacienti sú zaradení do klinického skúšania v rozpore s protokolom, ktorý spôsobila chyba na strane zdravotníckeho zariadenia alebo hlavného skúšajúceho. Protocol Violations: No payment will be provided in the event subjects are enrolled in violation of the Protocol due to the fault of Institution or Principal Investigator. Koncová platba: Koncová platba, ktorá zahŕňa aj nevyplatených pätnásť (15) percent, je splatná po dokončení záverečnej návštevy a po prijatí nasledovného: (i) kompletnej dokumentácie klinického skúšania, (ii) na vlastnú zodpovednosť prepočítaného počtu balení nepoužitého skúšaného liečivo, (iii) všetkých vyplnených a správnych záznamov CRF/námietok, (iv) všetkých žiadostí o objasnenie, o ktoré požiadal zadávateľ/PPD ohľadom údajov alebo záznamov klinického skúšania, (v) dodania záverečnej správy klinického skúšania etickej komisii a/alebo, podľa požiadaviek, inej kontrolnej inštitúcii. Final Payment: The final payment to include the fifteen percent (15%) withholding will be payable upon completion of the close-out visit and upon receipt of the following: (i) all Study documentation, (ii) the accountability of all unused Study Drug, (iii) all completed and correct eCRFs/queries (iv) any clarification requests made by Sponsor/PPD regarding Study data or records, (v) submission of final study report to EC and/or other Institution review committee as required.
EC Fees. I. POPLATEK EK: Local and central EC fees will be reimbursed directly by CRO/Sponsor unless otherwise specified herein. Poplatek lokální a centrální EK bude uhrazen přímo CRO/zadavatelem, pokud v tomto dokumentu není specifikováno jinak.
EC Fees. Sponsor shall reimburse Provider for EC fees in connection with the Study listed in the attached Budget. If Provider will be using the central EC, Sponsor will pay Provider’s EC fees directly to the central EC designated by Sponsor for the Study and will not reimburse Provider for EC fees incurred in connection with the Study.
AutoNDA by SimpleDocs

Related to EC Fees

  • L/C Fees Borrower shall pay to Agent for the account of each Lender in accordance with its Applicable Percentage an L/C fee (the “L/C Fee”) for each Letter of Credit equal to the Applicable Rate times the daily amount available to be drawn under such Letter of Credit. For purposes of computing the daily amount available to be drawn under any Letter of Credit, the amount of such Letter of Credit shall be determined in accordance with Section 1.06. L/C Fees shall be (A) due and payable on the first Business Day of each of April, July, October and January, in respect of the most recently-ended quarterly period (or portion thereof, in the case of the first payment), commencing with the first such date to occur after the issuance of such Letter of Credit, on the L/C Expiration Date and thereafter on demand and (B) computed on a quarterly basis in arrears. If there is any change in the Applicable Rate during any quarter, the daily amount available to be drawn under each Letter of Credit shall be computed and multiplied by the Applicable Rate separately for each period during such quarter that such Applicable Rate was in effect. Notwithstanding anything to the contrary contained herein, upon the request of the Required Lenders, while any Event of Default exists, all L/C Fees shall accrue at the Default Rate.

  • LC Fees The Borrower agrees to pay to the Administrative Agent, for the account of each Lender, a letter of credit fee at a rate per annum equal to the LC Fee Rate on such Lender’s Pro Rata Share of the undrawn stated amount of all Facility LCs for the period from the Effective Date to such Lender’s Termination Date (or, if later, the date on which such Lender has no participation interests in the Facility LCs), payable in arrears on the last day of each March, June, September and December and on the applicable Termination Date (and, if applicable, thereafter on demand). The Borrower also agrees to pay to the applicable LC Issuer for its own account (x) fronting fees in amounts and at times agreed upon between such LC Issuer and the Borrower and (y) documentary and processing charges in connection with the issuance or Modification of and draws under Facility LCs in accordance with such LC Issuer’s standard schedule for such charges as in effect from time to time.

  • ADS Fees The following ADS fees are payable under the terms of the Deposit Agreement: (1) Issuance of ADSs (e.g., an issuance upon a deposit of Shares, upon a change in the ADS(s)-to-Share(s) ratio, or for any other reason), excluding issuances as a result of distributions described in paragraph (4) below. Up to U.S. $5.00 per 100 ADSs (or fraction thereof) issued. Person for whom ADSs are issued. (2) Cancellation of ADSs (e.g., a cancellation of ADSs for Delivery of deposited Shares, upon a change in the ADS(s)-to-Share(s) ratio, or for any other reason). Up to U.S. $5.00 per 100 ADSs (or fraction thereof) cancelled. Person for whom ADSs are being cancelled. (3) Distribution of cash dividends or other cash distributions (e.g., upon a sale of rights and other entitlements). Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held. Person to whom the distribution is made. (4) Distribution of ADSs pursuant to (i) stock dividends or other free stock distributions, or (ii) an exercise of rights to purchase additional ADSs. Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held. Person to whom the distribution is made. (5) Distribution of securities other than ADSs or rights to purchase additional ADSs (e.g., spin-off shares). Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held. Person to whom the distribution is made.

  • Monthly Fees ACS will xxxx Customer each month during the term of this Agreement based on number of "Actions" which occurred during the prior month. The definition of "Actions" and fees for each Action will be documented in each Task Order. Customer shall cause ACS to be paid the foregoing fees on a monthly basis within thirty (30) days of ACS' delivery of an invoice for the preceding month's Actions.

  • Utilization Fees For any day on which the aggregate amount of Loans then outstanding exceeds fifty percent (50%) of the Commitments then in effect, or if any Loans remain outstanding after the Commitments have been terminated, then Borrower shall pay to the Administrative Agent for the ratable account of the Lenders in accordance with their Percentages a utilization fee accruing at a rate per annum equal to the Utilization Fee Rate on the aggregate amount of Loans outstanding on such date. Such utilization fee is payable in arrears on the last Business Day of each calendar quarter and on the Termination Date, and if the Commitments are terminated in whole prior to the Termination Date, the fee for the period to but not including the date of such termination shall be paid in whole on the date of such termination.

  • Interest Fees (a) Interest shall be payable on the Series 2004-4 Notes on each Distribution Date pursuant to Section 3.3. (b) On any Business Day, CRCF may, subject to Section 2.7(c), elect to allocate all or any portion of the Available CP Funding Amount with respect to any Match Funding CP Conduit Purchaser, to one or more CP Tranches with CP Rate Periods commencing on such Business Day by giving the Administrative Agent and the Funding Agent with respect to such Match Funding CP Conduit Purchaser irrevocable written or telephonic (confirmed in writing) notice thereof, which notice must be received by such Funding Agent prior to 3:00 p.m. (New York City time) on the second Business Day prior to such Business Day. Such notice shall specify (i) the applicable Business Day, (ii) the CP Rate Period for each CP Tranche to which a portion of the Available CP Funding Amount with respect to such Purchaser Group is to be allocated and (iii) the portion of such Available CP Funding Amount being allocated to each such CP Tranche. On any Business Day, CRCF may, subject to Sections 2.7(c) and 7.4, elect to allocate all or any portion of the Available APA Bank Funding Amount with respect to any Purchaser Group to one or more Eurodollar Tranches with Eurodollar Periods commencing on such Business Day by giving the Administrative Agent and the Funding Agent with respect to such Purchaser Group irrevocable written or telephonic (confirmed in writing) notice thereof, which notice must be received by such Funding Agent prior to 1:00 p.m. (New York City time) three (3) Business Days prior to such Business Day. Such notice shall specify (i) the applicable Business Day, (ii) the Eurodollar Period for each Eurodollar Tranche to which a portion of the Available APA Bank Funding Amount with respect to such Purchaser Group is to be allocated and (iii) the portion of such Available APA Bank Funding Amount being allocated to each such Eurodollar Tranche. Upon receipt of any such notice, the Funding Agent with respect to a Purchaser Group shall notify the CP Conduit Purchaser and the APA Bank with respect to such Purchaser Group of the contents of such notice promptly upon receipt thereof. (c) Notwithstanding anything to the contrary contained in this Section 2.7, (i) (A) each Match Funding CP Conduit Purchaser shall approve the length of each CP Rate Period and the portion of the Available CP Funding Amount with respect to such Match Funding CP Conduit Purchaser allocated to such CP Rate Period, (B) such Match Funding CP Conduit Purchaser may select, in its sole discretion, any new CP Rate Period if (x) CRCF does not provide notice of a new CP Rate Period on a timely basis or (y) the Funding Agent with respect to such Match Funding CP Conduit Purchaser, on behalf of such Match Funding CP Conduit Purchaser, determines, in its sole discretion, that the CP Rate Period requested by CRCF is unavailable or for any reason commercially undesirable and (C) the portion of the Available CP Funding Amount with respect to such Match Funding CP Conduit Purchaser allocable to each CP Tranche must be in an amount equal to $1,000,000 or an integral multiple of $100,000 in excess thereof and (ii) (A) the portion of the Available APA Bank Funding Amount with respect to any Purchaser Group allocable to each Eurodollar Tranche must be in an amount equal to $100,000 or an integral multiple of $100,000 in excess thereof, (B) no more than seven (7) Eurodollar Tranches with respect to such Purchaser Group shall be outstanding at any one time, (C) after the occurrence and during the continuance of any Amortization Event or Potential Amortization Event, CRCF may not elect to allocate any portion of the Available APA Bank Funding Amount with respect to any Purchaser Group to a Eurodollar Tranche and (D) during the Series 2004-4 Amortization Period, CRCF may not select any Eurodollar Period that does not end on or prior to the next succeeding Distribution Date. (d) On any Business Day, a Match Funding CP Conduit Purchaser may elect that CRCF no longer be permitted to select CP Tranches in accordance with Sections 2.7(b) and (c) in respect of the CP Conduit Funded Amount with respect to such CP Conduit Purchaser by giving CRCF and the Administrative Agent irrevocable written notice thereof, which notice must be received by CRCF and the Administrative Agent at least one Business Day prior to such Business Day. On any Business Day, a Pooled Funding CP Conduit Purchaser may with the prior written consent of the Administrator (which consent shall not be unreasonably withheld) elect thereafter to allow CRCF to select CP Tranches in accordance with Sections 2.7(b) and (c) in respect of the CP Conduit Funded Amount with respect to such CP Conduit Purchaser by giving CRCF and the Administrative Agent irrevocable written notice thereof, which notice and consent must be received by CRCF and the Administrative Agent at least one Business Day prior to such election. Any CP Conduit Purchaser making an election to change the manner in which its funding costs in respect of its Series 2004-4 Note are allocated in accordance with this Section 2.7(d) will be both a Match Funding CP Conduit Purchaser and a Pooled Funding CP Conduit Purchaser during the period that its Series 2004-4 Note is funded on both a “pooled” and “match funded” basis and its Monthly Funding Costs during that period will be calculated accordingly. (e) CRCF shall pay with funds available pursuant to Section 3.3(a) to the Administrative Agent, for the account of each Purchaser Group, on each Distribution Date, a commitment fee with respect to the Series 2004-4 Interest Period ending on the day preceding such Distribution Date (the “Commitment Fee”) during the period from the Series 2004-4 Closing Date to and including the Expiry Date with respect to such Purchaser Group at the Commitment Fee Rate of the average daily Commitment Amount with respect to such Purchaser Group during such Series 2004-4 Interest Period less the average daily Purchaser Group Invested Amount with respect to such Purchaser Group during such Series 2004-4 Interest Period. The Commitment Fees shall be payable monthly in arrears on each Distribution Date. (f) Calculations of per annum rates under this Supplement shall be made on the basis of a 360- (or 365-/366- in the case of interest on the Floating Tranche based on the Prime Rate) day year. Calculations of Commitment Fees shall be made on the basis of a 360-day

  • Support Fees Medical Practice shall be eligible to receive either Basic Support or Premium Support (the “Support Options”) based on the Support Option listed on Schedule “A” to the License Agreement. Medical Practice shall pay Modernizing Medicine the monthly fee specified on Schedule “A” of the License Agreement for either Basic Support (the “Basic Support Fee”) or Premium Support (the “Premium Support Fee” and together with the Basic Support Fee, the “Support Fees”) based on the Support Option that Medical Practice has selected. Medical Practice may elect to change the Support Option it has selected by providing at least ten (10) days prior written notice to Modernizing Medicine of such change, which change shall become effective at the commencement of the next applicable Renewal Term, unless otherwise agreed to in writing by Modernizing Medicine.

  • Interest Fees and Expenses (a) Interest on the Revolving Loans, whether bearing interest based on the Chase Bank Rate or LIBOR, shall be payable monthly as of the end of each month. Chase Bank Rate Loans shall be an amount equal to the Chase Bank Rate plus one quarter of one percent (.25%) per annum on the average of the net balances owing by the Company to CIT in the Revolving Loan Account at the close of each day during such month. In the event of any change in said Chase Bank Rate, the rate hereunder for Chase Bank Rate Loans shall change, as of the date of such change, so as to remain one quarter of one percent (.25%) above the Chase Bank Rate. The rate hereunder for Chase Bank Rate Loans shall be calculated based on a 360-day year. CIT shall be entitled to charge the Company's Revolving Loan Account at the rate provided for herein when due until all Obligations have been paid in full. (b) Notwithstanding any provision to the contrary contained in this section 8, in the event that the sum of the outstanding Revolving Loans exceed the lesser of either (x) the maximum aggregate amount available under Sections 3 and 5 of this Financing Agreement or (y) the Revolving Line of Credit: (A) as a result of Revolving Loans advanced by CIT at the request of the Company (herein "Requested Overadvances"), for any one (1) or more days in any month, or (B) for any other reason whatsoever (herein "Other Overadvances") and such Other Overadvances continue for five (5) or more days in any month , the average net balance of all Revolving Loans for such month shall bear interest at the Overadvance Rate. (c) Upon and after the occurrence of an Event of Default and the giving of any required notice by CIT in accordance with the provisions of Section 10, Paragraph 10.2 hereof, all Obligations shall bear interest at the Default Rate of Interest. 8.2 Interest on the Term Loan shall be payable monthly as of the end of each month on the unpaid balance or on payment in full prior to maturity. Chase Bank Rate Loans shall be in an amount equal to the Chase Bank Rate plus one half of one percent (.50%) per annum. In the event of any change in said Chase Bank Rate the rate hereunder for any such Chase Bank Rate Loans shall change, as of the date of such change, so as to remain one half of one percent (.50%) above the Chase Bank Rate. The rate hereunder shall be calculated based on a 360 day year. CIT shall be entitled to charge the Revolving Loan Account at the rate provided for herein when due until all Obligations have been paid in full. Notwithstanding the foregoing, if the Term Loan is not repaid in full by April 1, 2001, the rate of interest set forth in this Section 8.2 shall increase by one-half of

  • Admin Fees If, in any rolling three (3) Month period, two (2) or more MI Failures occur, the Supplier acknowledges and agrees that the Authority shall have the right to invoice the Supplier Admin Fees and (subject to paragraph 5.5) in respect of any MI Failures as they arise in subsequent Months.

  • Upfront Fees On the Effective Date, the Borrower shall pay to the Administrative Agent for the account of each Lender non-refundable upfront fees in the amounts set forth in letter agreements between each Lender and the Lead Arranger, and in an aggregate amount not to exceed the amount set forth in a letter agreement among the Borrower, the Administrative Agent and the Lead Arranger.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!